~~<i id='A2D1FFB18D'><strike id='A2D1FFB18D'><tt id='A2D1FFB18D'><pre id='A2D1FFB18D'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：fashion 2025-09-29 20:56:20 Page View：71

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Micronoma's microbiome cancer diagnostic approach under fire
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

U.K. officials, researchers try to ease path for bespoke genetic treatments

AdobeLONDON—Widespreadgenetictestingaswellasthedevelopmentofcutting-edge,customizedgenetictherapiesh

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Bring on the sabbaticals for nurses

AdobeA newstudy suggeststhatthenursingshortageiseasing,butthatdoesn’tmeanthehealthcaresystemcanstopw